In:
Tumori Journal, SAGE Publications, Vol. 68, No. 6 ( 1982-12), p. 527-530
Abstract:
Thirty patients without any prior chemotherapy and histologically proved non-oat-cell advanced lung cancer entered a randomized trial comparing a combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) and the same combination plus intradermic BCG. Twenty-nine patients were evaluable for survival. Mean survival was 11 and 3.5 months for chemotherapy and chemoimmunotherapy group, respectively. The difference was statistically significant (P 〈 0.025). A tumor enhancement can be postulated. Skin tests before treatment (PPD, Candida, Varidase) seem to be prognostic for survival.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/030089168206800613
Language:
English
Publisher:
SAGE Publications
Publication Date:
1982
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3